26.07
-0.07 (-0.27%)
| Previous Close | 26.14 |
| Open | 26.11 |
| Volume | 605,456 |
| Avg. Volume (3M) | 974,241 |
| Market Cap | 1,207,163,520 |
| Price / Earnings (Forward) | 9.62 |
| Price / Sales | 1.59 |
| Price / Book | 1.41 |
| 52 Weeks Range | |
| Earnings Date | 28 Jul 2025 - 1 Aug 2025 |
| Profit Margin | -14.76% |
| Operating Margin (TTM) | 4.63% |
| Diluted EPS (TTM) | -2.24 |
| Quarterly Revenue Growth (YOY) | 1.10% |
| Quarterly Earnings Growth (YOY) | -46.40% |
| Total Debt/Equity (MRQ) | 79.70% |
| Current Ratio (MRQ) | 2.41 |
| Operating Cash Flow (TTM) | 175.75 M |
| Levered Free Cash Flow (TTM) | 144.75 M |
| Return on Assets (TTM) | 3.56% |
| Return on Equity (TTM) | -12.27% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bearish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bearish | Mixed | |
| Stock | Pacira BioSciences, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | 1.5 |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -1.5 |
| Average | -0.30 |
|
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 1.73% |
| % Held by Institutions | 111.21% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 65.00 (HC Wainwright & Co., 149.33%) | Buy |
| Median | 47.50 (82.20%) | |
| Low | 30.00 (Needham, 15.08%) | Buy |
| Average | 47.50 (82.20%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 25.70 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 09 May 2025 | 30.00 (15.07%) | Buy | 25.12 |
| 08 Apr 2025 | 32.00 (22.75%) | Buy | 26.27 | |
| HC Wainwright & Co. | 08 Apr 2025 | 65.00 (149.33%) | Buy | 26.27 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BIGAL MARCELO | 24.34 | - | 6,163 | 150,007 |
| BREGE LAURA | 24.34 | - | 6,163 | 150,007 |
| CEESAY ABRAHAM | 24.34 | - | 6,163 | 150,007 |
| CHRISTIE CHRISTOPHER | 24.34 | - | 6,163 | 150,007 |
| FROIMSON MARK | 24.34 | - | 6,163 | 150,007 |
| KRONENFELD MARK A. | 24.34 | - | 9,999 | 243,376 |
| YANG MICHAEL J. | 24.34 | - | 6,163 | 150,007 |
| YOUNG ALETHIA | 24.34 | - | 6,163 | 150,007 |
| Aggregate Net Quantity | 53,140 | |||
| Aggregate Net Value ($) | 1,293,428 | |||
| Aggregate Avg. Buy ($) | 24.34 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BREGE LAURA | Director | 11 Jun 2025 | Acquired (+) | 6,163 | 24.34 | 150,007 |
| YOUNG ALETHIA | Director | 11 Jun 2025 | Acquired (+) | 6,163 | 24.34 | 150,007 |
| CHRISTIE CHRISTOPHER | Director | 11 Jun 2025 | Acquired (+) | 6,163 | 24.34 | 150,007 |
| YANG MICHAEL J. | Director | 11 Jun 2025 | Acquired (+) | 6,163 | 24.34 | 150,007 |
| BIGAL MARCELO | Director | 11 Jun 2025 | Acquired (+) | 6,163 | 24.34 | 150,007 |
| FROIMSON MARK | Director | 11 Jun 2025 | Acquired (+) | 6,163 | 24.34 | 150,007 |
| CEESAY ABRAHAM | Director | 11 Jun 2025 | Acquired (+) | 6,163 | 24.34 | 150,007 |
| KRONENFELD MARK A. | Director | 11 Jun 2025 | Acquired (+) | 9,999 | 24.34 | 243,376 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |